With a strong presence in key international markets like China, Grifols, S.A. (NASDAQ:GRFS) is well-positioned for long-term growth. Overall GRFS ranks 2nd on our list of the best low price pharma ...

Through a pioneering initiative called Chronos-PD, Grifols is partnering with the Michael J. Fox Foundation for Parkinson’s ...

In response, Grifols, a global leader in plasma science and the production of plasma-derived medicines, has embarked on a groundbreaking program in partnership with The Michael J. Fox Foundation ...

Grifols (GRFS) issued a statement to address certain information published in a media outlet on March 8, specifically a front-page article titled “The CNMV reveals to the judge ‘continuous ...

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes ...